Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.55 |
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | CPA1 | P15085 | 3/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602233 | 1.00 | MME (0.55) | MMEACECPA1ACE2 | |
| SCHEMBL29602011 | 1.00 | MME (0.55) | MMEACECPA1ACE2 | |
| SCHEMBL29602015 | 0.97 | CTSD (0.52) | MMEACECPA1ACE2 | |
| SCHEMBL29601916 | 0.97 | CTSD (0.52) | MMEACECPA1ACE2 | |
| SCHEMBL29601774 | 0.97 | CTSD (0.52) | MMEACECPA1ACE2 | |
| Mdl-28170 SCHEMBL7335375 | 0.93 | MME (0.61) | MMEACECPA1ACE2 | |
| Mdl-28170 SCHEMBL30873029 | 0.93 | MME (0.61) | MMEACECPA1ACE2 | |
| Mdl-28170 SCHEMBL11370994 | 0.93 | MME (0.61) | MMEACECPA1ACE2 | |
| SCHEMBL29602301 | 0.93 | BACE1 (0.59) | MME | |
| SCHEMBL31756753 | 0.92 | MME (0.52) | MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| CN-116350746-B | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| CN-122060643-A | Burkholderia BI1 strain and application thereof | 济南大学 | 2026-05-19 | — | — | CN | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| WO-2025002590-A1 | TISSUE MHC CLASS I IMMUNOPEPTIDE PATTERN DEDICATED FOR GENERATION OF ANTI-CANCER VACCINES AGAINST NON-SMALL CELL LUNG CANCER (NSCLC), IDENTIFICATION AND ISOLATION OF NSCLC SPECIFIC T CELLS IN HUMANS | UNIWERSYTET GDÁNSKI (PL) | 2025-01-02 | — | — | WO | disclosed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | disclosed |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | OGFR, OPRM1, CYP4F3 | MME 450/4885ACE 813/4885CPA1 1896/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | MME 824/4885ACE 1190/4885CPA1 245/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | MME 105/4885ACE 486/4885CPA1 126/4885 |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | MME 897/4885ACE 410/4885CPA1 2259/4885 |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OGFR | MME 371/4885ACE 739/4885CPA1 1254/4885 |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OGFR, OPRM1, CYP4F3 | MME 450/4885ACE 813/4885CPA1 1896/4885 |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | MME 112/4885ACE 132/4885CPA1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.